Gufic Biosciences (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Gufic Biosciences Limited |
|||
|
Price: ₹430.75 | ||
| 52 Week Low: ₹277.65 52 Week High: ₹504.25 |
|||
| Market Capital: 4,050.72 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Gufic Biosciences Share Price Target For 2024
- 1.1.1: Gufic Biosciences Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Gufic Biosciences Share Price Target For 2025
- 1.2.1: Gufic Biosciences Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Gufic Biosciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Gufic Biosciences Brief Company Overview
- 4: Gufic Biosciences Financial Performance
- 4.0.1: Is Gufic Biosciences A Good Buy For Long Term?
To predict the Gufic Biosciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Gufic Biosciences Share Price Target For 2024
The line chart displays the monthly closing prices of Gufic Biosciences with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Gufic Biosciences shares in 2024, see the table below.
Gufic Biosciences Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 454.0 (+5.39%) | Price Action: 18 Dec 2024 High |
| 2024 Target 2 | 448.0 (+4%) | Price Action: 06 Dec 2024 High |
| 2024 Target 1 | 439.5 (+2.02%) | Price Action: 04 Dec 2024 Low |
| Current Price | 430.75 | Gufic Biosciences's share price as of 23 Dec 2024 |
| Stop Loss 1 | 426.0 (-1.11%) | Price Action: 16 Dec 2024 Low |
| Stop Loss 2 | 421.7 (-2.11%) | Price Action: 21 Nov 2024 High |
| Stop Loss 3 | 416.0 (-3.43%) | Price Action: 26 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: Gufic Biosciences is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹428.61 serves as the nearest technical reference point.
Historical Returns: 3-month: +11.72% | 6-month: +24.85% | 1-year: +36.64%
Gufic Biosciences Share Price Target For 2025
The line chart displays the monthly closing prices of Gufic Biosciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Gufic Biosciences shares in 2025, see the table below.
Gufic Biosciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 594.73 (+38.06%) | Price Action: Chart |
| 2025 Target 2 | 583.64 (+35.49%) | Price Action: Chart |
| 2025 Target 1 | 577.86 (+34.15%) | Fibonacci Extension Level 64.90% |
| Current Price | 430.75 | Gufic Biosciences's share price as of 23 Dec 2024 |
| Stop Loss 1 | 396.2 (-8.02%) | Price Action: 21 Nov 2024 Low |
| Stop Loss 2 | 390.91 (-9.25%) | Fibonacci Retracement Level 50.00% |
| Stop Loss 3 | 386.85 (-10.19%) | Price Action: Jun 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Gufic Biosciences is currently trading at 67.6% of its 52-week range (₹277.65 - ₹504.25).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +36.64% | 3-year: +82.24% | 5-year: +617.63%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Gufic Biosciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹430.75 | ||
| 2024 | ₹389.81 | -9.5% | ₹395.66 |
| 2025 | ₹598.24 | +53.46% | ₹607.21 |
| 2026 | ₹749.62 | +25.3% | ₹760.86 |
| 2027 | ₹932.74 | +24.42% | ₹946.73 |
| 2028 | ₹951.90 | +2.05% | ₹980.34 |
| 2029 | ₹1,041.17 | +9.37% | ₹1,056.79 |
| 2030 | ₹1,347.49 | +29.42% | ₹1,367.70 |
| 2031 | ₹1,500.41 | +11.34% | ₹1,522.92 |
| 2032 | ₹1,711.04 | +14.03% | ₹1,736.71 |
| 2033 | ₹1,632.58 | -4.58% | ₹1,745.16 |
| 2034 | ₹1,692.54 | +3.67% | ₹1,936.45 |
| 2035 | ₹2,096.74 | +23.88% | ₹2,128.93 |
| 2036 | ₹2,251.20 | +7.36% | ₹2,294.76 |
| 2037 | ₹2,489.33 | +10.57% | ₹2,526.67 |
| 2038 | ₹2,313.27 | -7.07% | ₹2,513.89 |
| 2039 | ₹2,403.82 | +3.91% | ₹2,706.37 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Gufic Biosciences Brief Company Overview
Gufic Biosciences: A Reputable Manufacturer in Pharmaceuticals Established in 1970, Gufic Biosciences Limited is a renowned manufacturer of Active Pharmaceutical Ingredients (APIs), generic pharmaceuticals, and related services. Key Products: APIs for antifungals, anesthetics,...
immuno suppressants, and intermediates Lyophilized injections in various therapeutic segments Pharmaceutical, herbal, and personal care products Market Presence: Gufic Biosciences operates globally, with a strong presence in India and other regions including Africa, Asia, Europe, Australia, North America, and South America. Commitment: The company is committed to providing high-quality products and services to hospital chains and medical facilities, meeting the diverse needs of healthcare professionals and patients.Gufic Biosciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 4,050.72 Crore | Market valuation of Gufic Biosciences's shares. |
| Revenue (TTM) | 814.45 Crore | Total revenue generated by Gufic Biosciences over the past twelve months. |
| Net Income (TTM) | +86.36 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +15.51% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +10.6% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+4% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+1.09% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
62.51 | Company's total debt divided by total shareholder equity. |
| Total Debt | 332.91 Crore | Sum of Gufic Biosciences's current & long-term financial obligations. |
| Total Cash | 13.48 Crore | Total amount of liquid funds available to Gufic Biosciences. |
| Beta | 0.79 | Beta is less than 1 indicating that the Gufic Biosciences's price is less volatile than the market. |
Is Gufic Biosciences A Good Buy For Long Term?
Gufic Biosciences, a small-cap stock with a market capitalization of ₹4,050.72 crore, shows strong growth potential. While its Q2 2024-25 debt stands at ₹332.91 crore against a cash balance of ₹13.48 crore, impressive past returns (54.91% in the last 12 months, 331.80% over 5 years) and a healthy profit margin of 10.6% are positive indicators. However, its small size presents inherent risk. Considering its growth trajectory, it's an average buy for long-term investors with a moderate risk tolerance. Further due diligence is advised before investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
